What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
CDX2 is a protein that pathologists can detect in tumor tissue with an immunohistochemical stain. When tumor-cell nuclei stain for CDX2, the result supports intestinal differentiation and can make a colorectal origin more plausible—but it does not prove that the cancer began in the colon or rectum. Some non-colorectal tumors also express CDX2, and some colorectal cancers do not. Pathologists interpret it alongside the tumor’s appearance, other stains, prior specimens, imaging, and clinical history.
What CDX2 staining tells a pathologist
CDX2 is a transcription factor associated with the development and function of intestinal epithelial cells—the cells lining the intestine. In a pathology laboratory, immunohistochemistry (IHC) uses an antibody to make a particular protein visible in a tissue sample. A CDX2-positive result generally means the tumor cells show nuclear staining: the protein is detected in their nuclei.
That finding is evidence about the tumor’s differentiation, or the kind of cell program it resembles. It is not a label that directly identifies the organ where the tumor started. In a biopsy from a metastasis or a cancer whose primary site is uncertain, nuclear CDX2 positivity can support an intestinal source, including colorectal cancer. The pathologist still has to decide whether the whole picture fits that explanation better than alternatives.
This distinction matters because “intestinal-type” and “colorectal primary” are not interchangeable. Tumors arising elsewhere can acquire or retain intestinal features, and tumor cells can lose markers that would usually be expected for their origin. A stain is therefore most useful as one part of a diagnostic pattern rather than a stand-alone answer.
Why CDX2 is useful for identifying a colorectal pattern
Colorectal adenocarcinomas—the common gland-forming cancers of the colon and rectum—often show a recognizable combination of immunostains: CK7 negative, CK20 positive, and CDX2 positive. CK7 and CK20 are cytokeratins, proteins found in different patterns across epithelial tissues. Together with CDX2, they help characterize the tumor rather than independently name its primary site.
The European Society for Medical Oncology (ESMO) 2023 clinical practice guideline on cancer of unknown primary says: “At least 80% of CRCs show the classic CK7−/CK20+/CDX2+ immunophenotype, with CK20 and CDX2 staining usually being diffuse and strong.” The figure describes how often the classic pattern appears in colorectal cancers; it does not mean that a tumor with the pattern is at least 80% likely to be colorectal. That second question—how likely a positive pattern is to indicate colorectal origin—depends on which other tumors are under consideration and on the patient’s clinical circumstances.
For liver biopsies showing adenocarcinoma in a cancer-of-unknown-primary work-up, ESMO recommends CK7, CK20, CDX2, and TTF1 as part of the initial IHC panel. TTF1 can help assess certain lung and thyroid tumors, among other considerations. Additional stains are chosen to address the specific competing diagnoses, not simply added as a fixed checklist. The CSCO colorectal cancer guideline update also describes CK7-negative/CK20-positive/CDX2-positive as the typical immunophenotype of colorectal adenocarcinoma and advises selecting markers appropriate to the differential diagnosis.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsWhy a positive CDX2 result does not prove colorectal origin
CDX2 expression is associated with intestinal differentiation, not exclusively with cancers of the colon and rectum. Gastric and gastroesophageal tumors may express it, as can some pancreatic and biliary tumors. High-level expression has also been reported in mucinous ovarian and bladder adenocarcinomas. The result must be weighed against these and other possibilities that fit the tumor’s morphology, the biopsy site, and the clinical history.
Several studies show both why CDX2 is helpful and why it cannot settle the diagnosis by itself. Their percentages should be read as findings in the particular tumors and methods each study examined, not as universal test performance.
Rank #2
| Study and tumors examined | CDX2 or marker-pattern finding | How to interpret the result |
|---|---|---|
| Bayrak et al., 2012: 118 colorectal, 59 gastric, and 32 pancreatic adenocarcinomas | CDX2 was present in 114/118 colorectal tumors (97%), 36/59 gastric tumors (61%), and 5/32 pancreatic tumors (16%). | In this cohort CDX2 was common in colorectal tumors, but a positive result also occurred in gastric and pancreatic tumors. The study found CK7-negative/CK20-positive staining less sensitive but more specific for colorectal origin than CDX2 alone. |
| Survey of 476 primary and metastatic carcinomas, 2003 | CDX2 was uniformly expressed in all but one evaluated colorectal and duodenal tumor. High-level expression also appeared in mucinous ovarian and bladder adenocarcinomas; gastric, gastroesophageal, pancreatic, and biliary tumors showed variable expression. | Uniform expression was highly, but incompletely, specific for intestinal adenocarcinoma. The survey also illustrates that a marker can be strongly associated with a tissue program without being exclusive to one primary site. |
| Moskaluk et al., 2003: tissue-microarray survey of 745 cancers | Strong, extensive staining was seen in 90% of colonic adenocarcinomas; extensive staining was also seen in 20–30% of stomach, esophageal, and selected ovarian carcinomas. | Even extensive staining can overlap across tumor types. This survey’s figures describe its tissue-microarray sample and should not be treated as the expected rate in every laboratory or patient group. |
These studies used different tumor groups and methods, so their rates are not a head-to-head comparison. Results can vary with the antibody, the threshold used to call staining positive, the mix of tumors studied, and how differentiated the tumors are. A percentage from one selected study cannot, by itself, tell an individual patient the chance that a cancer began in the colorectum.
How CK7, CK20, and SATB2 add context
Pathologists look at the combination and distribution of stains. A CK7-negative, CK20-positive, CDX2-positive pattern supports colorectal differentiation more strongly than CDX2 positivity considered in isolation, but it is still not unique to colorectal cancer. The staining pattern, tumor architecture and cell features, and the site of the sampled tissue all contribute to the interpretation.
SATB2 is another marker that can be useful when colorectal origin is in the differential diagnosis. In a comparative study by Li et al. (2018), 222 colorectal cancers were assessed against 375 other carcinomas. The study reported these results:
| Marker strategy | Sensitivity in the study set | Specificity in the study set |
|---|---|---|
| CDX2 alone | 99% | 85% |
| CDX2 and CK20 | 92% | 93% |
| SATB2 and CK20 | 90% | 98% |
In that study, sensitivity means how often the marker strategy identified colorectal cancers in the tested group; specificity means how often it was negative in the non-colorectal comparison group. Adding a second marker changed the balance: SATB2/CK20 had lower sensitivity but higher specificity than CDX2 alone in that set. The authors also found SATB2 combinations with CK20 or villin more specific than the corresponding CDX2 dual stains, with broadly comparable sensitivity. These figures describe the study’s selected tumors, not a universal performance guarantee or a protocol that must be used for every biopsy.
The choice of stains depends on the actual diagnostic question. A pathologist may add SATB2 or other markers when they could help distinguish colorectal cancer from plausible mimics. CK7, CK20, CDX2, TTF1, and any additional markers are interpreted as a panel suited to the specimen and clinical differential—not as a score in which every positive stain contributes the same amount of proof.
What happens when CDX2 is negative
A negative CDX2 stain does not rule out colorectal cancer. Some colorectal tumors lose CDX2 expression, particularly tumors with poor differentiation or other biologically distinct features. The expected intestinal marker pattern may become less complete as tumor cells become less like the mature tissue from which they arose.
Recommended Free Tools
A 2024 study assessed CDX2 and SATB2 phenotypes in 269 colorectal cancers. Loss of SATB2 and/or CDX2 was associated with poorly differentiated histotypes, mucus production, and mismatch-repair-deficient phenotypes. These associations help explain why a tumor can be colorectal in origin yet fail to show one or more expected markers. They do not mean every poorly differentiated or mismatch-repair-deficient colorectal cancer will be negative.
When CDX2 is absent, the pathologist considers whether other stains, the tumor’s microscopic features, previous tissue samples, or clinical evidence support a colorectal origin. A negative result is one finding to reconcile with the rest of the case, not a reason to discard the diagnosis automatically.
Why morphology and patient history can decide an apparent match
Immunostains are interpreted alongside morphology: what the tumor looks like under the microscope, including its architecture and cellular features. A pathologist also considers where the sample was taken, whether the patient has a known prior cancer, what imaging shows, and whether an earlier specimen can be compared directly. These details help distinguish a new primary cancer from a metastasis and assess whether a marker pattern fits the full case.
The importance of clinical context is not just theoretical. Among 684 non-colorectal tumors examined in the 2024 study, investigators encountered an ovarian mucinous cystadenocarcinoma with a CK7-negative/CK20-positive/CDX2-positive/SATB2-positive profile. Its marker pattern could not be distinguished from metastatic colorectal cancer without the patient’s history and clinical information. Multiple supportive stains had still left an overlap that the broader case had to resolve.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →This is why a pathology report’s stain results should be read as part of its final interpretation, not as isolated yes-or-no answers. If the report discusses a possible colorectal origin, it is describing how the findings fit together—not claiming that CDX2 alone identifies the original organ.
How to read a CDX2 result in a pathology report
For patients reviewing a report, the most useful questions concern the pathologist’s overall conclusion and the evidence behind it. The stain’s result matters, but its meaning depends on the other findings in the same specimen and on the clinical question being investigated.
- Check the diagnostic conclusion. Look for the final diagnosis or comment, which integrates the tumor’s appearance and the full set of stains.
- Read the panel, not one marker in isolation. Note whether the report describes CK7, CK20, SATB2, TTF1, or other relevant markers alongside CDX2.
- Connect the finding to the specimen and history. A biopsy from a suspected metastasis is interpreted differently from a sample of a known primary, and prior cancer records or imaging may change the differential.
- Ask what remains uncertain. If the report describes an intestinal phenotype or says colorectal origin is favored, ask the treating clinician or pathologist how that conclusion relates to other possible primary sites and the clinical findings.
CDX2 IHC is a laboratory test performed on tissue and interpreted by trained pathology professionals; it is not a consumer test for determining the site of a cancer. A patient should not use a positive or negative marker result alone to diagnose a primary cancer or change treatment. Questions about an individual report belong with the treating clinician, who can interpret it alongside the complete pathology, imaging, and medical history.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What CDX2 can—and cannot—establish
CDX2 is useful because it can support intestinal differentiation and, in the right morphologic and clinical setting, strengthen the case for colorectal origin. The common CK7-negative/CK20-positive/CDX2-positive pattern and companion markers such as SATB2 give pathologists a more informative picture than any one stain can provide. But overlap with other tumors and loss of staining in some colorectal cancers limit what the marker can establish alone. Final assignment of a primary site comes from integrated pathology and clinical assessment.
Frequently Asked Questions
Is CDX2 specific for colorectal cancer?
No. CDX2 supports intestinal differentiation and is often present in colorectal adenocarcinoma, but it can also be expressed in gastric, gastroesophageal, pancreaticobiliary, mucinous ovarian, bladder, and other tumors. A positive result is interpreted with other stains, tumor morphology, and clinical history.
Can CDX2 be positive in cancers that started outside the digestive tract?
Yes. Some mucinous ovarian and bladder adenocarcinomas can show CDX2, and some tumors from other sites may express it variably. This overlap is why CDX2 alone cannot establish the primary site.
Does a negative CDX2 result rule out colorectal cancer?
No. Some colorectal cancers, including subsets associated with poor differentiation or mismatch-repair-deficient phenotypes, may lose CDX2 and/or SATB2. The result must be considered with the rest of the pathology and clinical evidence.
Why might a pathologist order CK7, CK20, SATB2, or TTF1 with CDX2?
These markers provide a pattern that can help assess competing tumor origins. CK7, CK20, CDX2, and TTF1 may be included in an initial panel for a liver biopsy showing adenocarcinoma of unknown primary; SATB2 can add useful specificity in suitable cases. The panel is selected for the specimen and diagnostic question, and no combination replaces clinical correlation.
The Bottom Line
CDX2 can support an intestinal, and sometimes colorectal, origin, but neither a positive nor negative result settles the diagnosis alone. Pathologists interpret it with other markers, morphology, prior specimens, imaging, and clinical history.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
